September 28, 2018 / 3:32 PM / a year ago

Takeda's $62 billion Shire bid faces November 6 EU antitrust deadline

FILE PHOTO: Shire branding is seen outside their offices in Dublin, Ireland, April 25, 2018. REUTERS/Clodagh Kilcoyne/File Photo

BRUSSELS (Reuters) - EU antitrust regulators will decide by Nov. 6 whether to allow Japanese drugmaker Takeda Pharmaceutical’s (4502.T) $62-billion takeover of London-listed Shire Plc SHP.L, the European Commission said on Friday.

The EU competition enforcer can give the green light with or without demanding concessions or open a four-month long investigation if it has serious concerns.

The deal, the largest overseas acquisition by a Japanese company, would elevate the combined company into the list of the top 10 global drugmakers. It would be a leader in gastroenterology, neuroscience, oncology, rare diseases and blood-derived therapies used for serious conditions such as haemophilia.

Authorities in the United States, China and Brazil have already given unconditional approvals for the deal.

Reporting by Foo Yun Chee; Editing by Emelia Sithole-Matarise

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below